Nimodipine vs. Milrinone - Equal or Complementary Use? A Retrospective Analysis.
cerebral vasospasm
delayed cerebral ischemia
endovascular procedures
milrinone
nimodipine
subarachnoid hemorrhage
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
05
2022
accepted:
21
06
2022
entrez:
1
8
2022
pubmed:
2
8
2022
medline:
2
8
2022
Statut:
epublish
Résumé
Cerebral vasospasm (CVS) continues to account for high morbidity and mortality in patients surviving the initial aneurysmal subarachnoid hemorrhage (SAH). Nimodipine is the only drug known to reduce delayed cerebral ischemia (DCI), but it is believed not to affect large vessel CVS. Milrinone has emerged as a promising option. Our retrospective study focused on the effectiveness of the intra-arterial application of both drugs in monotherapy and combined therapy. We searched for patients with aneurysmal SAH, angiographically confirmed CVS, and at least one intra-arterial pharmacological angioplasty. Ten defined vessel sections on angiograms were assessed before and after vasodilator infusion. The improvement in vessel diameters was compared to the frequency of DCI-related cerebral infarction before hospital discharge and functional outcome reported as the modified Rankin Scale (mRS) score after 6 months. Between 2014 and 2021, 132 intra-arterial interventions (144 vascular territories, 12 bilaterally) in 30 patients were analyzed for this study. The vasodilating effect of nimodipine was superior to milrinone in all intradural segments. There was no significant intergroup difference concerning outcome in mRS ( The monotherapy with intra-arterial nimodipine was superior to milrinone. Nimodipine and milrinone may be used complementary in an escalation scheme with the administration of nimodipine first, complemented by milrinone in cases of severe CVS. Milrinone monotherapy is not recommended.
Sections du résumé
Background
UNASSIGNED
Cerebral vasospasm (CVS) continues to account for high morbidity and mortality in patients surviving the initial aneurysmal subarachnoid hemorrhage (SAH). Nimodipine is the only drug known to reduce delayed cerebral ischemia (DCI), but it is believed not to affect large vessel CVS. Milrinone has emerged as a promising option. Our retrospective study focused on the effectiveness of the intra-arterial application of both drugs in monotherapy and combined therapy.
Methods
UNASSIGNED
We searched for patients with aneurysmal SAH, angiographically confirmed CVS, and at least one intra-arterial pharmacological angioplasty. Ten defined vessel sections on angiograms were assessed before and after vasodilator infusion. The improvement in vessel diameters was compared to the frequency of DCI-related cerebral infarction before hospital discharge and functional outcome reported as the modified Rankin Scale (mRS) score after 6 months.
Results
UNASSIGNED
Between 2014 and 2021, 132 intra-arterial interventions (144 vascular territories, 12 bilaterally) in 30 patients were analyzed for this study. The vasodilating effect of nimodipine was superior to milrinone in all intradural segments. There was no significant intergroup difference concerning outcome in mRS (
Conclusions
UNASSIGNED
The monotherapy with intra-arterial nimodipine was superior to milrinone. Nimodipine and milrinone may be used complementary in an escalation scheme with the administration of nimodipine first, complemented by milrinone in cases of severe CVS. Milrinone monotherapy is not recommended.
Identifiants
pubmed: 35911878
doi: 10.3389/fneur.2022.939015
pmc: PMC9330364
doi:
Types de publication
Journal Article
Langues
eng
Pagination
939015Informations de copyright
Copyright © 2022 Jentzsch, Ziganshyna, Lindner, Merkel, Mucha, Schob, Quäschling, Hoffmann, Werdehausen, Halama, Gaber and Richter.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Crit Care Nurs Q. 2020 Apr/Jun;43(2):138-156
pubmed: 32084059
Pharmacol Ther. 1995;68(1):1-34
pubmed: 8604432
Interv Neuroradiol. 2017 Dec;23(6):636-643
pubmed: 28956512
Neurocrit Care. 2021 Dec;35(3):669-679
pubmed: 34478028
J Neurosurg. 1990 Apr;72(4):626-33
pubmed: 2319321
Stroke. 2010 Aug;41(8):e519-36
pubmed: 20595669
J Neuroradiol. 2019 Feb;46(1):15-24
pubmed: 29733918
Stroke. 2022 Aug;53(8):2607-2616
pubmed: 35674046
Stroke. 2011 Apr;42(4):919-23
pubmed: 21350201
Neurocrit Care. 2019 Aug;31(1):32-39
pubmed: 30725331
Neurosurgery. 2001 Apr;48(4):723-8; discussion 728-30
pubmed: 11322432
Eur Heart J. 1993 Nov;14 Suppl I:141-8
pubmed: 8293765
J Neurosurg Anesthesiol. 2018 Jul;30(3):281-283
pubmed: 28225470
Cardiovasc Hematol Agents Med Chem. 2009 Jul;7(3):206-11
pubmed: 19689259
Neuroradiology. 2011 Feb;53(2):123-8
pubmed: 20549498
Stroke. 2010 Oct;41(10):2391-5
pubmed: 20798370
Acta Neurochir (Wien). 2022 Mar;164(3):811-821
pubmed: 35138488
J Neurosurg Anesthesiol. 2021 Jul 1;33(3):195-202
pubmed: 33480639
Front Neurol. 2019 Feb 21;10:136
pubmed: 30858818
J Neurointerv Surg. 2018 Jul;10(7):638-643
pubmed: 29760013
AJNR Am J Neuroradiol. 2008 Jun;29(6):1053-60
pubmed: 18372422
Stroke. 1981 Jul-Aug;12(4):501-8
pubmed: 7314173
Acta Neurochir (Wien). 2017 Apr;159(4):713-720
pubmed: 28224318
Clin Neuroradiol. 2013 Jun;23(2):87-95
pubmed: 23010691
J Neurol Surg A Cent Eur Neurosurg. 2021 Nov 22;:
pubmed: 34808678
Transl Stroke Res. 2021 Jun;12(3):428-446
pubmed: 33078345
Neurosurg Rev. 2021 Dec;44(6):3107-3124
pubmed: 33682040
World Neurosurg. 2022 Apr;160:e412-e420
pubmed: 35033694